[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 14477
1. Baiocchi GL, Villanacci V, Rossi E, Zanotti D, Giulini SM: EGF-R Protein Expression and Gene Amplification do not Correlate in Pancreas Cancer. Gastroenterology Res; 2008 Dec;1(1):55-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGF-R Protein Expression and Gene Amplification do not Correlate in Pancreas Cancer.
  • : In a series of 13 pancreas cancer specimens, EGF-R was evaluated by means of both immunohistochemistry (IHC) for protein expression and FISH for genetic amplification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994708.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; EGF-R / FISH / cancer / immunohistochemistry / pancreas
  •  go-up   go-down


2. Liu MJ, Shin S, Li N, Shigihara T, Lee YS, Yoon JW, Jun HS: Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1. Mol Ther; 2007 Jan;15(1):86-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Type 1 diabetes results from insulin deficiency caused by destruction of pancreatic β cells.
  • The number of insulin-positive cells in the pancreas and insulin secretion significantly increased in rAd-GLP-1-treated mice compared with STZ-induced diabetic mice treated with rAd-β-galactosidase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182934.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Terada T: Non-functioning Well Differentiated Endocrine Carcinoma of the Pancreas. Gastroenterology Res; 2009 Dec;2(6):364-366

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-functioning Well Differentiated Endocrine Carcinoma of the Pancreas.
  • : The author reports a typical but rare case of non-functioning well differentiated endocrine carcinoma of the pancreas.
  • He has no familiar history of pancreatic neoplasms.
  • Various imaging modalities including US, CT and MRI revealed a tumor of the pancreatic body.
  • A solid well demarcated tumor was present in the pancreatic body.
  • Immunohistyochemically, tumor cells were positive for cytokeratin, synaptophysin, neuron-specific enolase, and CD56; they were negative for chromogranin, gastrin, glucagon, somatostatin, pancreatic polypeptide, and vasoactive intestinal polypeptide.
  • The pathological diagnosis was non-functioning well differentiated endocrine carcinoma of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990210.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Endocrine carcinoma / Histopathology / Immunohistochemistry / Pancreas
  •  go-up   go-down


Advertisement
4. Bedoui R, Nouira R, Najah N, Dziri C: [Intraductal papillary mucinous tumor of the pancreas mimicking pancreatic pseudocyst]. Tunis Med; 2010 Jun;88(6):445-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraductal papillary mucinous tumor of the pancreas mimicking pancreatic pseudocyst].
  • [Transliterated title] Une Tumeur Intracanalaire Papillaire et Mucineuse du Pancreas Simulant un Faux Kyste du Pancreas.
  • BACKGROUND: Most of pancreatic cysts are in fact pseudocysts.
  • Intraductal papillary mucinous tumors of the pancreas represent nearly 15% of them.
  • AIM: To illustrate, by an observation, the difficulties to diagnose a cystic tumor of the pancreas.
  • CASE REPORT: We report the case of a 55 year old woman complaining of epigastric pain for one month with an elevated pancreatic enzymes level.
  • Ultrasonography and computed tomography scan showed two cystic formations measuring 6 and 7 cm localized respectively in the head and the body of the pancreas.
  • The diagnosis of pancreatic pseudocysts was maintained.
  • It revealed an intraductal papillary mucinous tumor of the pancreas affecting secondary ducts.
  • CONCLUSION: The diagnosis of intraductal papillary mucinous tumor of the pancreas must be referred to in case of pancreatic cystic tumor without extrapancreatic necrosis.
  • This kind of tumor can simulate a pancreatic pseudocyst.
  • [MeSH-major] Carcinoma, Intraductal, Noninfiltrating / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatic Pseudocyst / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517860.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


5. Bedioui H, Chebbi F, Ayadi S, Daghfous A, Bakhtri M, Jouini M, Fteriche F, Ksantini R, Kacem M, Safta ZB: [Primary hydatid cyst of the pancreas: Diagnosis and surgical procedures. Report of three cases]. Gastroenterol Clin Biol; 2008 Jan;32(1 Pt. 1):102-6
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary hydatid cyst of the pancreas: Diagnosis and surgical procedures. Report of three cases].
  • [Transliterated title] Kyste hydatique primitif du pancreas: diagnostic et modalites chirurgicales. A propos de trois cas.
  • The pancreas is an uncommon site of a hydatid cyst, even in countries where echinococcal disease is endemic.
  • We report three cases of primary hydatid cysts of the pancreas revealed by abdominal pain.
  • The diagnosis was based on ultrasound and CT-scan, which showed a cystic mass in the tail of the pancreas in the two first cases.
  • In the third case, the diagnosis was determined preoperatively and a pancreatic fistula was found in the head of the pancreas during peroperative cholangiography.
  • [MeSH-major] Echinococcosis / diagnosis. Pancreatic Diseases / parasitology
  • [MeSH-minor] Abdominal Pain / parasitology. Anastomosis, Surgical. Cholangiography. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pancreatectomy. Pancreatic Ducts / surgery. Pancreatic Fistula / parasitology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405655.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


6. Noguchi H, Oishi K, Ueda M, Yukawa H, Hayashi S, Kobayashi N, Levy MF, Matusmoto S: Establishment of Mouse Pancreatic Stem Cell Line. Cell Transplant; 2009 May/Jun;18(5-6):563-572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of Mouse Pancreatic Stem Cell Line.
  • Pancreatic stem/progenitor cells could become a useful target for β-cell replacement therapy in diabetic patients because the cells are abundantly available in the pancreas of these patients and in donor organs.
  • In this study, we established a mouse pancreatic stem cell line without genetic manipulation.
  • Exendin-4 treatment and transduction of PDX-1 and NeuroD proteins by protein transduction technology in HN#13 cells induced insulin and pancreas-related gene expression.
  • This cell line could be useful for analyzing pancreatic stem cell differentiation.
  • Moreover, the isolation technique might be useful for identification and isolation of human pancreatic stem/progenitor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880635.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; BETA2/NeuroD / Exendin-4 / PDX-1 / Pancreatic duct / Pancreatic stem cell / Protein transduction domain
  •  go-up   go-down


7. Tai JH, Sun H, Liu W, Melling CWJ, Hasilo C, White DJG: Isolating Human Islets of Langerhans Causes Loss of Decay Accelerating Factor (CD55) on β-Cells. Cell Transplant; 2008 Dec;17(12):1349-1359
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established that DAF was expressed in islets and on β-cells prior to isolation by in situ analysis in the intact pancreas.
  • In situ immunohistochemistry (IHC) was used to examine DAF expression on human pancreatic islets and isolated islets.
  • A reverse transcriptase-polymerase chain reaction (RT-PCR) specific for human DAF mRNA was developed to measure mRNA levels in situ in islets within the intact pancreas, isolated islets, and purified β-cells.
  • Expression of DAF protein was present on the islets, including β-cells within the human pancreas; however, comparative data from IHC and flow cytometry revealed the absence of DAF protein on β-cells in both isolated islets and single cell preparations.
  • Furthermore, compared to mRNA levels detected by in situ RT-PCR in the intact pancreas and in human HEK 293 cells, isolated islets, and purified human β-cells showed downregulation of DAF mRNA. mRNA was detectable in both of these preparations by RT-PCR; levels were lower following both the islet isolation process (53%) and single cell preparation (a further 62%) compared to HEK 293 controls.
  • Human islet allotransplantation might be more successful if either de novo transfer of DAF onto the isolated islets or novel techniques for islet isolation preserving DAF could be developed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876096.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; CD55) / Complement / Decay accelerating factor (DAF / Instant blood-mediated inflammatory reaction (IBMIR) / Islet isolation / Transplantation; β-Cells
  •  go-up   go-down


8. Van Der Windt DJ, Echeverri GJ, Ijzermans JNM, Cooper DKC: The Choice of Anatomical Site for Islet Transplantation. Cell Transplant; 2008 Sep;17(9):1005-1014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These factors result in the loss of many transplanted islets, mainly during the first hours or days after transplantation, which could in part explain the necessity for the transplantation of islets from multiple pancreas donors to cure type 1 diabetes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863751.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Immune privilege / Intraportal / Islet transplantation / Omental pouch / Subcutaneous / Xenotransplantation
  •  go-up   go-down


9. Martin M: Clinical Experience With Pemetrexed in Breast Cancer. Semin Oncol; 2006 Feb;33 Suppl 2:15-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alimta (pemetrexed) is a novel multitargeted antifolate that inhibits several enzymes in the de novo pathways of pyrimidine and purine biosynthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.
  • Pemetrexed possesses antitumor activity in several solid tumors, including non-small cell lung cancer, malignant pleural mesothelioma, pancreas, colorectal, gastric, bladder, breast, and head and neck cancers.
  • Some studies have suggested that a correlation exists between thymidylate synthase tumor expression with pemetrexed antitumor activity; this attractive hypothesis should be confirmed in further studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140044.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sharif S, Broman M, Babcock T, Ong E, Jho D, Rudnicki M, Helton WS, Espat NJ: A Priori Dietary Ω-3 Lipid Supplementation Results in Local Pancreatic Macrophage and Pulmonary Inflammatory Response Attenuation in a Model of Experimental Acute Edematous Pancreatitis (AEP). JPEN J Parenter Enteral Nutr; 2006;30(4):271-276

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Priori Dietary Ω-3 Lipid Supplementation Results in Local Pancreatic Macrophage and Pulmonary Inflammatory Response Attenuation in a Model of Experimental Acute Edematous Pancreatitis (AEP).
  • BACKGROUND: Acute pancreatitis is often complicated by multiorgan dysfunction, which is postulated to occur in part by macrophage infiltration into the pancreas.
  • We hypothesized that dietary EPA supplementation before the induction of pancreatitis would attenuate both Mϕ-mediated local pancreatic and systemic pulmonary inflammatory response in an in vivo model of acute edematous pancreatitis (AEP).
  • Pancreas, lung, and serum were harvested 3 hours after the last cerulein injection.
  • Pancreatic macrophage infiltration was assessed by confocal fluorescent microscopy, and pulmonary leukocyte respiratory burst (LRB) analysis was performed on mononuclear cells obtained from bronchioalveolar lavage (BAL).
  • CONCLUSIONS: Attenuation of both pancreatic MΦ inflammatory response and pulmonary leukocyte respiratory burst in AEP by EPA supports further investigation into the potential role for EPA dietary supplementation in the progression of pancreatitis-associated sequelae.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28059011.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kin T, Rosichuk S, Shapiro AMJ, Lakey JRT: Detection of Microbial Contamination during Human Islet Isolation. Cell Transplant; 2007 Jan;16(1):9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluid samples for microbial contamination were collected at the following steps: from the pancreas transport solution upon arrival of the organ (n = 157), after surface decontamination of the pancreas with antiseptic agents (n = 89), from islet supernatant at the end of the isolation (n = 104), and from islet supernatant as a final transplantable product after culture (n = 53).
  • Surface decontamination of the pancreas resulted in clearance of 92% of the microbial contamination.
  • All were de novo contamination during the processing.
  • Microbial contamination in final products is rare, but de novo contamination still occurs during processing even under cGMP conditions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880675.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Antibiotics / Islet isolation / Microbial contamination / Quality control
  •  go-up   go-down


12. Noguchi H, Naziruddin B, Onaca N, Jackson A, Shimoda M, Ikemoto T, Fujita Y, Kobayashi N, Levy MF, Matsumoto S: Comparison of Modified Celsior Solution and M-Kyoto Solution for Pancreas Preservation in Human Islet Isolation. Cell Transplant; 2010 Jun;19(6-7):751-758

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Modified Celsior Solution and M-Kyoto Solution for Pancreas Preservation in Human Islet Isolation.
  • Since the successful demonstration of the Edmonton protocol, islet transplantation has advanced significantly on several fronts, including improved pancreas preservation systems.
  • HNC) solution and modified Kyoto (MK) solution were compared for pancreas preservation prior to islet isolation.
  • However, there was no significant difference in ATP content in the pancreata or in the attainability of posttransplant normoglycemia in diabetic nude mice between the two groups, suggesting that the quality of islets was similar among the two groups.
  • In conclusion, MK solution is better for pancreas preservation before islet isolation than HNC solution due to the higher percentage of islets that can be isolated from the donor pancreas.
  • MK solution should be the solution of choice among the commercially available solutions for pancreatic islet isolation leading to transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28871822.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Islet transplantation / Modified Celsior solution / Modified Kyoto solution / Preservation solution
  •  go-up   go-down


13. Yuasa T, Rivas-Carrillo JD, Navarro-Alvarez N, Soto-Gutierrez A, Kubota Y, Tabata Y, Okitsu T, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N: Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2. Cell Transplant; 2009 May/Jun;18(5-6):683-688

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of a bioartificial pancreas (BAP) with immunoisolating fashion has been gaining attention as a new method for treating diabetes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880643.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Bioartificial pancreas / Fibroblast growth factor 2 / Neovascularization
  •  go-up   go-down


14. Domínguez-Bendala J, Pastori RL, Ricordi C, Inverardi L: Protein Transduction: A Novel Approach to Induce In Vitro Pancreatic Differentiation. Cell Transplant; 2006 Jan;15(1_suppl):85-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein Transduction: A Novel Approach to Induce In Vitro Pancreatic Differentiation.
  • It is widely believed that human embryonic stem (huES) cells may represent a valid alternative to donor pancreata as a source of islets for transplantation.
  • Much is known about the transcription factors whose sequential activation results in the generation of islets during pancreatic development.
  • However, our understanding of the extracellular signals that prompt the developing pancreas to follow this sequence of molecular events is very limited.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863758.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; In vitro differentiation / Islet transplantation / Protein transduction / Stem cells
  •  go-up   go-down


15. Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Prowda J, Schreibman S, Levitz J: Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.
  • This GTX regimen was designed to inhibit MEK-ERK phosphorylation and increase BAX and BAK and also decrease BCL-2 in pancreatic cancer cell lines.
  • Based on these findings, we pursued a prospective clinical trial evaluating the activity of GTX in previously untreated patients with metastatic pancreatic cancer.
  • METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.
  • Scans were completed every 9 to 10 weeks to assess for tumor response by RECIST criteria.
  • CONCLUSIONS: The combination of gemcitabine, docetaxel, and capecitabine has activity in metastatic pancreatic cancer with a median survival over 1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Osoegawa A, Takeda Y, Kometani T, Ondo K, Fukuyama S, Hirai F, Nosaki K, Seto T, Oda S, Ichinose Y: LKB1 mutations in mucinous bronchioloalveolar carcinoma occurring in Peutz-Jeghers syndrome patients. J Clin Oncol; 2009 May 20;27(15_suppl):11047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11047 Background: Mutations in the gene encoding Liver Kinase B1, LKB1, are common in patients with Peutz-Jeghers syndrome (PJS), which is characterized by mucocutaneous pigmentation, intestinal polyps and a high incidence of cancers at variable sites (colorectal, gynecological, breast, pancreas, and lung).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Albouy B, Billemont B, Massard C, Gross-Goupil M, Rixe O, Escudier B: Pancreatic metastasis from renal cell carcinoma: Presentation, recurrence, survival, and response to antiangiogenic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16137

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis from renal cell carcinoma: Presentation, recurrence, survival, and response to antiangiogenic therapy.
  • : e16137 Background: Pancreas represents an uncommon site of metastasis in renal cell carcinoma (RCC).
  • The natural history of pancreatic metastases is largely unknown, and efficacy of targeted agents has never been assessed.
  • We examined the outcome in a series of RCC patients (pts) with pancreatic metastases, treated by either surgery or antiangiogenic therapy.
  • METHODS: We reviewed the charts of RCC pts treated for pancreatic metastases, between 2001 and 2008, in Institut Gustave Roussy and Pitié-Salpetrière Hospital.
  • Data base was reviewed to determine presentation, clinical symptoms, pancreatic metastases treatment, use of systemic therapy, disease-free survival (DFS) or progression-free survival (PFS) and overall survival (OS) after treatment.
  • RESULTS: A total of 40 pts with pancreatic metastases from RCC have been analyzed.
  • Surgical resection of pancreatic metastases was performed in 8 (20%) patients, and DFS and OS were 45 and 66 months.
  • CONCLUSIONS: Patients with RCC pancreatic metastases seem to have a longer survival than the usual metastatic RCC pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963352.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ottochian M, Yang D, El-Khoueiry A, Iqbal S, Pohl A, Zhang W, Ning Y, Lenz HJ: Association of gender, age, and ethnicity with survival in patients with pancreas cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of gender, age, and ethnicity with survival in patients with pancreas cancer.
  • : e15587 Background: Pancreatic cancer (PC) is the fourth leading cause of cancer death in the United States.
  • These included 24,240 patients diagnosed with localized pancreatic cancer (LPC) and 26,062 patients with metastatic pancreatic cancer (MPC).
  • RESULTS: On multivariate analysis gender, age, race, marital status, tumor size, grade, histology, type of treatment and lymph node involvement were found to be independent predictors of survival.
  • These data also warrant further in vitro and in vivo investigations on the mechanisms of estrogen and pancreas progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ubillos L, Berois N, Mazal D, Braña V, Yacoel C, Masllorens A, Berriel E, Rondan M, Carriquiry L, Osinaga E: Involvement of ppGalNAc-T6, a new colon cancer marker, in the molecular basis of simple mucin-type O-glycosylated antigen expression. J Clin Oncol; 2009 May 20;27(15_suppl):e15060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We found that ppGalNAc-T6 (an enzyme usually restricted to normal placenta, trachea, brain, and pancreas) is expressed by colon cancer cell lines.
  • CONCLUSIONS: ppGalNac-T6 is a new tumor marker for colon cancer and its expression is related with the accumulation of two O-glycosylated antigens such as Tn and core 6.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964510.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hauser KA, Karafa M, Seyidova-Khoshknabi D, Davis MP, Walsh D: Prevalence and risk factors of vitamin D insufficiency in cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Electronic medical records of all adult solid tumor patients treated at The Cleveland Clinic in 2006-2007 were reviewed.
  • Insufficiency was associated with male gender, race (African American), month of test (Feb-Apr, Oct), cancer type (hepatobiliary, genitourinary, pancreas, upper gastrointestinal), metastatic disease, low albumin, high bilirubin and AST, and lack of antineoplastic or vitamin D medication (all p<0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Saunders M, Anthoney A, Coffey M, Mettinger K, Thompson B, Melcher A, Nutting CM, Harrington K: Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was objective tumor response rate in treated lesions.
  • RESULTS: 16 heavily pre-treated pts (9 male, median age 66 yrs, ECOG 0:4pts; 1:12pts) with advanced cancer: melanoma (5), colorectal (4), gastric (1), ovarian (1), pancreas (1), lung (1), cholangiocarcinoma (1), sinus (1), and thyroid (1) were enrolled since Dec 2006.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963520.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Cil T, Tuzun AY, Altintas A, Batum S, Isikdogan A, Yurt M: Reduced folat carrier gene status in colorectal, gastric, and pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e13540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced folat carrier gene status in colorectal, gastric, and pancreatic cancer.
  • The aim of this prospective study; was documenting RFC gene status in gastric, colorectal and pancreatic cancers in southeast region of Turkey.
  • METHODS: We were evaluated homozygote, heterozygote mutations of RFC (SLC19A1) and wild type of RFC in new diagnosis gastric, colorectal and pancreas cancer patients who presented at the medical oncology and gastroenterology divisions of the Dicle University Hospital in Turkey between the dates August 2007 and October 2008 in southeast region of Turkey.
  • RESULTS: We were evaluated gene status of RFC in 62 (50%) colorectal, 45 (36.3%) gastric and 17 (13.7%) pancreatic cancer patients.
  • In colorectal cancer patients group; 28 (45.9%), 19 (31.1%), 14 (23%), in gastric cancer 29 (64.4%), 7 (15.6%), 9 (20%), in pancreatic cancer 11 (64.7%), 2 (11.8%), 4 (23.5%) heterozygote, homozygote and wild type gene status, respectively.
  • We think that antifolat drugs will be used in colorectal, gastric and pancreatic cancer patients in standard treatment protocols and RFC gene status will be an important of antifolat drugs activity in these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ueno M, Ohkawa S, Sakamoto Y, Miyakawa K, Miyagi Y: The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer.
  • : e15629 Background: The standard chemotherapy of advanced pancreatic cancer is still gemcitabine and recently gemcitabine + EGFR tyrosine kinase inhibitor (TKI)is noted to be positive on Phase III study.
  • On the other hand, such EGFR mutations were not reported to be recognized by the direct sequencing method in pancreatic cancer.
  • This time we examined EGFR expressions and EGFR mutations in advanced pancreatic cancer.
  • METHODS: We examined EGFR expressions immunohistochemically and EGFR mutations by Loop-Hybrid Mobility Shift Assay (LH-MSA) which is more sensitive than the direct sequencing method in the tissue obtained from percutaneous biopsies in advanced pancreatic cancer patients.
  • RESULTS: The subjects were 31 inoperable pancreatic cancer patients.
  • The tissues were obtaind from liver; 12, pancreas; 19.
  • CONCLUSIONS: EGFR expressions were not correlated with survivals and the same EGFR mutations as lung cancer were not detected in inoperable advanced pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Picozzi VJ, Canlas LA, Sicuro PL, Malpass TW: A phase II trial of gemcitabine, docetaxel, and bevacizumab (GDB) in metastatic pancreas cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4606

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gemcitabine, docetaxel, and bevacizumab (GDB) in metastatic pancreas cancer.
  • : 4606 Background: Metastatic pancreas cancer (MPC) remains identified with poor outcome.
  • Eligiblity criteria included 1) diagnosis of MPC, 2) chemotherapy naivity, 3) ECOG performance status 0 /1, 4) organ function adequate for therapy.
  • Secondary endpoints included therapy toxicity, radiographic RR (RECIST criteria), tumor marker RR (CA 19.9) and OS.
  • To date, disease control at 8 wks is 100% (24/24 pts) radiographic RR is 48% (12/25 pts) and tumor marker RR is 95% (18/19 evaluable pts expressed CA19.9, median decline 80%, 5 pts normalized) .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Gasent Blesa J, Alberola Candel V, Giner Marco V, Juan O, Provencio Pulla M, Llorca C, Gravalos C: Phase II trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp). J Clin Oncol; 2009 May 20;27(15_suppl):e15561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp).
  • : e15561 Background: Gemcitabine (G) based chemotherapy is the standard treatment for patients (Pt) with pancreatic cancer.
  • We performed this prospective phase II trial to evaluate the efficacy and safety of the combination of Ox and Cp in second-line pancreatic cancer chemotherapy.
  • Gender: male/female 8/7, mean age was 64.1 years (47-82), in Pt with elevated CA-19.9 at diagnosis mean CA-19.9 was 337.6 (47-689).
  • Mean time from diagnosis to initiation of second line chemotherapy was 219.3 days (121-457).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Dickson MA, Carvajal RD, Shah M, Tse AN, Dials H, Cane LM, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol. J Clin Oncol; 2009 May 20;27(15_suppl):e14511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types: colorectal, gastric, HCC, GE junction, small bowel, pancreas, bile duct, breast, bladder, ovarian, sarcoma, melanoma, anal, urethral, thymic, head & neck, unknown primary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Viret F, Ychou M, Baey C, Bennouna J, Adenis A, Peiffert D, Mornex F, Celier P, Montoto-Grillot C, Ducreux M: A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial.
  • : 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.
  • The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel and cisplatin in histologically proven adenocarcinoma of the pancreas.
  • RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.
  • Location of the tumor: head (33 pts), body (13 pts), and tail (5 pts).
  • 6 pts underwent secondary pancreatic resection (4 compete resection and 1 pt with histological complete remission).
  • CONCLUSIONS: The association docetaxel+cisplatin+radiotherapy has limited effect in patients with locally advanced pancreatic carcinoma but major objective responses have been observed allowing secondary resections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Vogelstein B: Cancer genomes and their implications for understanding and managing cancer. J Clin Oncol; 2009 May 20;27(15_suppl):s1a

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of such sequencing in 68 tumors of the breast, colon, pancreas, or brain have led to new insights about the nature and diversity of the genetic alterations responsible for initiation and progression of tumors.
  • The challenge for clinical science is to devise approaches to use this new and extensive genetic information to improve diagnosis and therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 11 patients received kidney, two lung and one liver, one heart and one pancreas transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Gold D, Modrak DE, Newsome G, Karanjawala Z, Hruban R, Goggins M, Goldenberg DM: Detection of early-stage pancreatic carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of early-stage pancreatic carcinoma.
  • : 4613 Background: Invasive pancreatic carcinoma is a virtually lethal disease, mostly because of the failure to detect it at a sufficiently early timepoint for successful treatment.
  • Our laboratory has identified a unique biomarker detected by MAb PAM4 that shows high specificity for a mucin glycoprotein expressed by pancreatic carcinoma (PC).
  • While identified in almost 90% of PC and its precursor lesions, the antigen is not detectable in normal pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence TS, Abrams R, Leslie W, Zalupski M: Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer.
  • : 4602 Background: Current treatments of non-metastatic, unresectable pancreatic cancer result in poor survival and nearly uniform local persistence of disease.
  • METHODS: Eligibility included tissue diagnosis of adenocarcinoma, unresectable by radiological criteria, Zubrod performance of 0-2, ANC of ≥ 1500/mm3, platelets ≥ 100,000/mm3, creatinine < 2 mg/dl, bilirubin < 3 mg/dl, ALT and AST ≤ 2.5 x ULN, and informed consent.
  • GTV was defined on pancreas protocol CT in the treatment position.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Greco FA, Spigel DR, Yardley DA, Erlander M, Ma X, Hainsworth JD: Unknown primary cancer (UPC): Accuracy of tissue of origin prediction by molecular profiling. J Clin Oncol; 2009 May 20;27(15_suppl):11070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We then compared the RT-PCR diagnosis with the subsequent clinical diagnosis.
  • METHODS: 38 of 501 UPC pts (7%) seen between 2000 and 2008 had their primary tumor subsequently identified during life.
  • RESULTS: 16 of 24 assays were successful (8 had no tumor or RNA in the material).
  • 11 of 16 predictions of the site of origin (68%) were correct, corresponding to the actual primary sites found 3-58 months (median 8.5 months) after the initial diagnosis of UPC.
  • 3 predictions were inaccurate (colorectal, testicular, sarcoma) in patients with gastroesophageal, pancreas and NSCLC, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963186.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Sankhala KK, Mita AC, Adinin R, Wood L, Beeram M, Bullock S, Yamagata N, Matsuno K, Fujisawa T, Phan A: A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J Clin Oncol; 2009 May 20;27(15_suppl):2535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2535 Background: MBP-426 is a novel liposome encapsulated oxaliplatin (L-OHP) formulation bound to human transferrin, developed to improve the safety and efficacy of L -OHP through the prolongation of circulation time and by targeting transferrin receptors on tumor cells.
  • Tumor response was assessed by RECIST.
  • The common tumor types were colorectal 23 (60%), pancreas 3 (8%), and neuroendocrine 3 (8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Nallapareddy S, Gustafson D, Leong S, Messersmith W, Arnott J, Eckhardt SG, Sidor C, Camidge DR: A single-center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients (pts) with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3562 Background: ENMD-1198 (2-methoxyestra-1, 3, 5, (10) 16-tetraene-3-carboxamide), an analog of 2-methoxyestradiol (2ME2), has both antiangiogenic and antiproliferative effects in various tumor types.
  • METHODS: Eligible pts had advanced cancer for which no effective therapy exists that is either evaluable by RECIST criteria or tumor markers that could be monitored for clinical benefit.
  • One pt (neuroendocrine ca pancreas) is experiencing prolonged SD at 60 mg/m<sup>2</sup>/d >14 cycles and a 2nd pt (prostate ca) experienced SD at 30mg/m<sup>2</sup>/d for 10 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Li J, Kluger H, Saif MW, Murren JR, Lee JJ, Kelly WK, Rink L, Devine L, Sznol M: A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3554 Background: Sirolimus, a commercially available oral mTOR inhibitor, may complement the anti-angiogenic and anti-tumor activity of sunitinib, an oral small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), by vertical disruption of VEGFr signaling, by reducing the compensatory production of VEGF in sunitinib-treated patients, and also by directly inhibiting tumor cell proliferation.
  • Four pts received >4 cycles (5-STS, 5-renal papillary, 13-neuroendocrine pancreas, 17-renal clear cell).
  • These results suggest caution when combining targeted agents lacking specificity for tumor signaling or vasculature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961367.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Hamm JT, Richards D, Ramanathan RK, Becerra C, Jameson G, Walling J, Gribben D, Dhar S, Eldon M, Von Hoff D: Dose-finding study of NKTR-102 in combination with cetuximab. J Clin Oncol; 2009 May 20;27(15_suppl):e13503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Eighteen pts were enrolled: main tumor types include colon (5), pancreas (4), rectal (2), breast (2), gastric (1), other (4).
  • Another pt with pancreatic cancer had a decrease in CA19-9 from 2000 at baseline to 157 U/ml with associated symptomatic benefit.
  • Data support further evaluation of this combination in appropriate tumor types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961254.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Brown D, Boyd A, Henrickson C, Hampton J, Almani F, Ben-Josef E, Zalupski M, Simeone D, Taylor J, Armitage R, Riba M: Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas. J Clin Oncol; 2009 May 20;27(15_suppl):e15678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas.
  • : e15678 Purpose: To evaluate the prevalence of depression, sleep related disturbances and anxiety and their effect on quality of life in patients with recently diagnosed adenocarcinoma of the pancreas who present to a multidisciplinary pancreatic cancer clinic.
  • A minority (2 pts, 8%) had PSWQ scores characteristic of an anxiety disorder, while 33% (8 pts) had moderate anxiety scores.
  • CONCLUSIONS: Our results indicate that mild to moderate depressive symptoms, anxiety and potential sleep problems are common in patients referred to a multidisciplinary pancreatic cancer clinic.
  • To better characterize the relationship of depression (and potential causes) with pancreatic cancer, additional prospective longitudinal studies are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Christiansen CF, Johansen MB, Christensen S, Langeberg W, Fryzek JP, Toft Sørensen H: Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark. J Clin Oncol; 2009 May 20;27(15_suppl):9570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we examined the incidence of AKI within the first year after cancer diagnosis to estimate the magnitude of this risk and better understand which patients are at greatest risk.
  • Baseline sCr was defined as the lowest sCr in the year before cancer diagnosis.
  • We compared this value to the highest sCr on record during the first year following cancer diagnosis to identify those who experienced an AKI.
  • Incidence was highest among patients aged 80 years or older (531 per 1,000 person-years, 95% CI 464-606) and in those with cancer of the liver (1,221, 95%CI 676-2,205), pancreas (1,472, 95%CI 1,130-1,917), or kidney (1,254, 95%CI 974-1,616), or with multiple myeloma (855, 95%CI 538-1,356).
  • Our study showed that over 20% of cancer patients may experience acute kidney injury in the first year after diagnosis.
  • Older patients and those with cancer of the liver, pancreas, or kidney, or with multiple myeloma are especially at risk for AKI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963659.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Bukhari MH, Byron E, Strosberg JR, Nasir NA, Henderson-Jackson E, Bui M, Hakam A, Domenico C, Kvols L, Nasir A: Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15616

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15616 Background: Primary gastro-entero-pancreatic poorly differentiated neuroendocrine carcinomas (GEP-PDNECAs) are highly aggressive neoplasms with a very poor prognosis.
  • DATA SOURCES: Pathology archives, consultation files, tumor registry and social security index.
  • Sites: Colo-rectum 39, pancreas 19, small intestine (SI) 4, stomach 3, colon/SI/pancreas 3.
  • CONCLUSIONS: Diagnosis of GEP-PDNECA can be based on histo-morphologic features and expression of neuroendocrine markers.
  • Synaptophysin was the most sensitive marker; however, a panel of 2 or 3 neuroendocrine markers (Syn, Cg and CD56) may be more useful to avoid under-diagnosis of GEP-PDNECA, especially in the metastatic setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962728.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Carr BI, Summers D, Menefee L, Pierpoint S, Yeo C, Kennedy E, Lavu H: Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20692

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis.
  • : e20692 Background: In order to begin to understand the effects of disease on the patient (pt) and possibly of the pt on the disease, we have begun a systematic psychological inventory of all our pts who have has a pancreatectomy for pancreas adenocarcinoma and have began to correlate this with disease extent, and later with survival.
  • The data was entered into a database, together with pertinent lab results, tumor markers, and tumor characteristics from the pre-op CT scan and post-op pathology report.
  • RESULTS: Descriptive means (and ranges) were - tumor size 3.43 cm mean (2.0 min-5.2 max), bilirubin 1.26 (0.2-4.7), albumin 2.69 (1.5-3.6), Hb 10.3 (7.5-13.2), platelets 254K (109K-672K), CEA 4.7 (0.8-24), and Ca 19-9 was 987 (1.0-8127).
  • Statistically significant correlations were found for tumor size and pain severity (p<.035), platelets and FWB (p<.022), albumin and Hb (p=.000), CA 19-9 and bilirubin (p<.030 i.e. high CA 19-9 and high bilirubin).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961756.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Rosario C, Gladdy R, Ko M, Pollett A, Dennis J, Swallow C: Elucidating genetic events in human hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 4q is a commonly deleted region in HCC and is lost in 32% of premalignant cirrhotic nodules but the precise molecular lesion involved in tumor initiation remains unknown.
  • Plk4 is a haploinsufficient tumor suppressor in mice, with 50% of animals developing spontaneous tumors, most commonly multifocal primary HCC.
  • Our purpose was to determine the levels of Plk4 in human HCC and investigate possible genetic interactions with the tumor suppressor p53.
  • Studies in CRC (n=46) and pancreas cancer specimens (n=40) showed only background levels of LOH.
  • Expression of Plk4 in HCC tumor samples that displayed LOH at the Plk4 locus was reduced compared to non-neoplastic liver.
  • Plk4<sup>±</sup>p53<sup>-/-</sup> mice showed acceleration of tumor formation compared to Plk4<sup>+/+</sup>p53<sup>-/-</sup> mice.
  • In addition, our studies of compound mutant mice suggest a possible genetic interaction of Plk4 and p53 in tumor development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962886.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Lee J, Lee S, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S: Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA). J Clin Oncol; 2009 May 20;27(15_suppl):e15553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA).
  • : e15553 Background: To determine the efficacy and safety of fixed dose rate (FDR) gemcitabine and capecitaibne (GX) combination chemotherapy for locally advanced pancreatic adenocarcinoma Methods: Patients with histologically confirmed LAPA were eligible for this prospective phase II trial.
  • Dynamic pancreas/pelvic CT, MRI and FDG-PET were undertaken to assess the resectability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Sausville E, Garbo L, Weiss GJ, Anthony S, Shkolny D, Yurkovetskiy AV, Bethune C, Fram RJ: A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • XMT-1001 demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenograft models, providing a compelling rationale for its clinical development.
  • Stable disease was observed in 7 pts with the following tumor types and dose levels expressed in mg CPT equivalents/m<sup>2</sup>: NSCLC (1.0 mg/m<sup>2</sup>, 6 wks), ovarian (4.9 mg/m<sup>2</sup>, 12 wks), pancreas (4.9 mg/m<sup>2</sup>, 36 wks), appendiceal (7.3 mg/m<sup>2</sup>, 12 wks), bile duct (9.1 mg/m<sup>2</sup>, 18 wks), basal cell (11.6 mg/m<sup>2</sup>, 6 wks), and colon (15.4 mg/m<sup>2</sup>, 6 wks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961894.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Dennie T, Alberti D, Oliver K, LoConte N, Mulkerin D, Wilding G, Holen K, Fleming R, Bowen C, O'Neill V: A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One pt had breast cancer and the remainder had non- colorectal GI malignancies (esophagus, hepatobiliary, and pancreas).
  • One pt with pancreatic cancer had a confirmed partial response (PR) to treatment, and 3 others had stable disease for > 90 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Sangha R, Ho C, Beckett L, Lau DH, Lara PN, Davies AM, Mack PC, Koslan GM, Holland WS, Gandara DR: Dual epidermal growth factor receptor (EGFR) inhibition: Phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 18 pts were treated: 13 NSCLC, 3 H&N, 1 pancreas, and 1 invasive thymoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961369.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A: Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3511 Background: Src kinase is central to the proliferation, apoptosis and metastasis of tumor cells.
  • KX2-391 has a much wider spectrum of solid tumor activity in vitro, and is more potent in mouse xenografts, as compared to other multikinase Src/Abl inhibitors.
  • 7 pts had prolonged stable disease for 4 months or longer including 2 pts with papillary thyroid carcinoma, 2 with carcinoid, and 1 each with prostate, pancreas, and head and neck cancer.
  • Both the prostate and pancreatic cancer pts had dramatic decreases in their biomarkers (PSA went from 205 ng/ml to 39 ng/ml, and CA19-9 went from 38,838 U/ml to 267 U/ml, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Gromada J, Franklin I, Wollheim CB: α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains. Endocr Rev; 2007 Feb 01;28(1):84-116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28199574.001).
  • [ISSN] 1945-7189
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Trukova K, Gupta D, Vashi PG, Adams A, Lambert GM, Grutsch JF, Lammersfeld CA: Serum 25-hydroxy vitamin D and nutritional status: Implications for vitamin D assessment and dietary supplementation in oncology. J Clin Oncol; 2009 May 20;27(15_suppl):9638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancer types were lung (133, 18%), breast (131, 17.8%), colorectal (97, 13.2%), pancreas (86, 11.7%), prostate (44, 6%) and ovarian (38, 5.2%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963933.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Lee R, Von Roenn J: Is best supportive care really best supportive care? J Clin Oncol; 2009 May 20;27(15_suppl):9639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 43 studies met our inclusion criteria (publication dates, 1980-2008) with the following cancer types: 22 lung cancer, 6 colorectal, 6 pancreas, 2 gastric, and 7 other cancer types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963931.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Brell JM, Hardacre J, Schulak J, Onders R, Stellato T, Sanabria J, Schulchter M, Strickland L, Sprosty R, Pink J: Characterization of human skeletal muscle in weight-losing pancreatic cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of human skeletal muscle in weight-losing pancreatic cancer patients.
  • : 9571 Background: Decreased body mass (cachexia) is a common cause of functional decline in pancreas carcinoma (PC) and other malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963662.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. McKay CE, Infante J, Jones S, Bendell J, Greco FA, Markus TM, Spigel DR, Yardley DA, Woudenberg J, Lathia CD, Burris HA: A pharmacokinetic (PK) and safety study of sorafenib plus capecitabine in advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types include colon (4), pancreas (2), prostate (2), and other (11).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963620.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Golshayan AR, Elson P, Wood LS, Garcia JA, Dreicer R, Rini BI: Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Clin Oncol; 2009 May 20;27(15_suppl):5043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib.
  • : 5043 Background: An important goal of non-curative therapy for mRCC is tumor burden (TB) control.
  • However, the impact of tumor burden characteristics on clinical outcome has not been studied in mRCC pts treated with VEGF-targeted therapy.
  • CT scan images were re-reviewed from baseline, at the time of maximal tumor burden shrinkage (TS), at time of disease progression and at time of last assessment prior to death.
  • Sites of metastases included: lung (87%), mediastinal lymph nodes (52%), retroperitoneal lymph nodes (36%), adrenal (29%), bone (38%), liver (22%), pancreas (14%), kidney (7%), and brain (6%).
  • Total number of metastases <10 (p < 0.001) and tumor volume above the diaphragm <6.5 cm (p = 0.05) were independent positive predictors of OS.
  • At time of disease progression (PD), tumor location and pattern of progression were not associated with OS.
  • CONCLUSIONS: Tumor burden shrinkage and tumor burden at time of disease progression are associated with overall survival in pts with mRCC treated with sunitinib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962954.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pecout S, Baudin E, Paoli A, Maire F, Terrebonne E, Mitry E, Pavel M, Ruszniewski P, Cadiot G, Brixi-Benmansour H, Groupe des Tumeurs Endocrines (GTE): Efficacy and tolerance of chemotherapy with dacarbazine or temozolomide associated or not with 5-fluorouracil (5-FU) in endocrine carcinomas: A retrospective multicentric study from the Groupe des Tumeurs Endocrines (GTE). J Clin Oncol; 2009 May 20;27(15_suppl):e15523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerance of chemotherapy with dacarbazine or temozolomide associated or not with 5-fluorouracil (5-FU) in endocrine carcinomas: A retrospective multicentric study from the Groupe des Tumeurs Endocrines (GTE).
  • Primaries were : pancreas (n=34), digestive tract (n=23), thyroid (n=9), lung (n=6), other (n=6), unknown (n=8).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Nilsson B, Hendlisz A, Castella M, Aamdal S, Dueland S, Nyakas M, Evans J, Venugopal B, Rasch W, Awada A: First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stabilisation of disease (≥ 3 months) reported in 5 pts (pancreas, colon and ovarian cancer) lasting between 3.5 to 8 months.
  • One ovarian pt had a 28.3% reduction in tumor mass.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961893.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Lustberg MB, Nuovo J, Thomas JP, Monk PJ 3rd, Kim S, Villalona-Calero M, Bekaii-Saab T: Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. J Clin Oncol; 2009 May 20;27(15_suppl):2569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study.
  • The beneficial interactions of paclitaxel and carboplatin in upregulation of TP promise to make capecitabine more tumor specific and to provide the expected synergy.
  • There were 10 confirmed responses [4 CR (esophagus, stomach, unknown primary and ampullary); 6 PRs (Pancreas (3), unknown primary, anal and esophagus] and stabilization of disease > 3 months in 12 patients.
  • Two phase II trials are already underway at OSU using this regimen for patients with pancreatic cancer and adenocarcinomas of unknown primary, the latter already actively enrolling patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Gupta D, Trukova K, Vashi PG, Adams A, Lambert GM, Lammersfeld CA: Association of serum 25-hydroxy vitamin D and body mass index in cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most common cancers were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreas (86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961800.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Read WL, Rosen P, Lee P, Anthony S, Korn R, Raghunand N, Tseng B, Whisnant J, Von Hoff D, Tibes R: Pharmacokinetic and pharmacodynamic results of a 4-hr IV administration phase I study with EPC2407, a novel vascular disrupting agent. J Clin Oncol; 2009 May 20;27(15_suppl):3569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an earlier phase I study dosing by 1 hr infusions daily x3 on a 21 day cycle, DLT at 21 mg/m<sup>2</sup> was pain at tumor sites and vasoconstriction with increases of BP and QTc.
  • Prolonged infusion of EPC2407 to extend exposure of tumor vasculature was designed with administration of EPC2407 over 4 hrs for 3 consecutive days of a 21 day cycle.
  • Eleven patients have received this schedule and their cancers included leiomyosarcoma, colo-rectal, ovary, hepatocellular (2), NSCLC, pancreas, carcinoid, hemangiopericytoma, larynx and small bowel.
  • DLTs at 30 mg/m<sup>2</sup> were similar to those seen in the 1 hr infusion, with pain at tumor sites in 1 participant and asymptomatic ST depression in a second.
  • Analysis to date of DCE-MRI data of 4 patients showed a median decrease of 40% in both tumor permeability (K<sub>trans</sub>) and tumor perfusion volume (Vp).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Bascioni R, Giorgi F, Safi M, Giustini L, De Signoribus G, Silva R: Chemotherapy in very elderly cancer patients (85 years and over): A retrospective study. J Clin Oncol; 2009 May 20;27(15_suppl):e20632

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Type of cancer (pts): NSCLC (13), colorectal (11), breast (5), prostate (4), gastric (3), NHL (3), bladder (2), head-neck (2), ovarian (2), vulvar (1), skin (1), pancreas (1), GIST (1), UPT (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961580.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Lindhofer H, Schoberth A, Pelster D, Hess J, Herold J, Jäger M: Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study. J Clin Oncol; 2009 May 20;27(15_suppl):3014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3014 Background: Putative cancer stems cells (CSCs) are defined as "tumor-initiating cells" that have the capacity to self-renew and to give rise to the variety of differentiated cells found in the malignancy.
  • The trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab efficiently eliminates tumor cells from the peritoneal fluid of malignant ascites (MA) patients as demonstrated in a pivotal phase II/III trial (Parsons et al., ASCO 2008).
  • METHODS: 18 CTX-refractory patients with MA caused by a variety of primary carcinoma diseases (i.e., ovarian, pancreas, and gastric cancer) were analyzed for the presence CD133+/EpCAM+ cells in peritoneal fluids by means of CD133+/EpCAM+ double staining on cytospin preparations.
  • CONCLUSIONS: In a preliminary monitoring study, putative CSCs (CD133+/EpCAM+) were present in peritoneal fluids of 78 % of analyzed MA patients with different underlying primary tumor entities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Kinzbrunner B, Tanis D: Average length of stay in hospice for five cancers. J Clin Oncol; 2009 May 20;27(15_suppl):6593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We reviewed the records of 73,263 patients with prostate, colorectal, breast, lung, or pancreatic cancer who were admitted to one of 45 hospice programs and died on service between January 2000 and December 2007.
  • ALOS for prostate, colorectal, breast, lung, and pancreas was 46.8, 44.9, 44.2, 37.3, and 31.4 days, respectively.
  • Prostate, colorectal, and breast ALOS were not significantly different from one other; lung ALOS was less than the top three but greater than pancreas ALOS (p < 0.001); and pancreas ALOS was significantly lower than all others (p < 0.001).
  • CONCLUSIONS: The longer ALOS for patients with prostate, colorectal and breast cancer may be related to differences in natural history and effectiveness of anti-neoplastic therapies when compared to cancers of the lung and pancreas.
  • Given the remarkable stability of ALOS over the last eight years and the lack of a statistical interaction between year and type of cancer, ALOS differences also suggest a steeper rate of decline for patients with cancers of the lung and pancreas following admission to hospice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963856.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Erbersdobler A, Simon R, Hellwinkel OJ, Bokemeyer C, Sauter G, Hu-Lowe D, Levin W, Gallo-Stampino C, Fiedler W: Analysis of expression of TGF-β1 receptor (ALK-1) in normal and tumor tissues by tissue microarrays. J Clin Oncol; 2009 May 20;27(15_suppl):e22044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of expression of TGF-β1 receptor (ALK-1) in normal and tumor tissues by tissue microarrays.
  • Here we describe target validation in normal and tumor tissue using tissue micro-arrays (TMAs).
  • Multi-tumor arrays consisted of 3923 individual tumor samples from 87 tumor types.
  • RESULTS: ALK-1 staining of vessels in normal tissues was generally weak (mostly grade 1 and rarely grade 2) and was detectable in lymphatic tissues including tonsil, lymph nodes, thymus and spleen, lung, the entire GI tract including parotid, submandibular and sublingual glands as well as pancreas.
  • In human tumor vessels ALK-1 expression showed high variability between tumor types.
  • The highest ALK-1 expression rate was found in lung cancer (NSCLC 49%, SCLC 83%), neuroendocrine pancreas tumor (71%), colon cancer (50%), chondrosarcoma 50%, angiosarcoma 40% and NHL (44%).
  • CONCLUSIONS: TMAs are an excellent tool to verify target expression in normal and tumor tissues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963226.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Evens AM, David KA, Helenowski I, Kircher SM, Mauro L, Gimelfarb A, Hattersley E, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):8510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 81 PTLD pts were identified (SOT: 47 kidney ± pancreas, 4 pancreas, 17 liver, 8 heart, 5 lung) with median age at diagnosis (dx) of 48 yrs (range 20-72).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960875.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The primary outcome measures of the study were (1) to assess the radiological tumor response;.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Morine Y, Shimada M, Imura S, Uchiyama H, Uchiyama H, Kanemura H, Arakawa Y, Hanaoka J, Sugimoto K: Clinical role of regulatory T cell in intraductal papillary mucinous neoplasms. J Clin Oncol; 2009 May 20;27(15_suppl):e15537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15537 Background: Intraductal papillary mucinous neoplasms of pancreas (IPMNs) have malignant potential and exhibit a broad histologic spectrum, ranging from adenoma to invasive carcinoma.
  • Recently, several investigators have reported that regulatory T cells (Foxp3+CD4+ T cells including CD4+CD25+ T cells and CD4+CD25- T cells) play important roles in anti-tumor immunity.
  • We previously reported clinical role of increased populations of Foxp3+CD4+ T cells (Treg) in peripheral blood from advanced pancreatic cancer patients (Pancreas 2006).
  • METHODS: Thirty-five patients with IPMNs (IPMC: n=8, IPMB: n=2, IPMA: n=5) and pancreas cancer (n=20) who underwent surgical resection were included in this study.
  • Immunohistochemical expression of Foxp3 (abcam: FOXP3 antibody, 236A/E7), Fascin (Dako: Fascin antibody, 55K-2) and TGF-β (Santa Cruz: TGF-β1 antibody, SC146) in main tumor was assessed in all IPMN patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962313.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Donato Di Paola E, Alonso S, D'Alessio A, Giuliani R, Calabrò F, Messina C, Zivi A, Squilloni E, De Marco S, Sternberg C: Dose finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group B. 11 pts with no prior chemotherapy (4 hepatocarcinoma, 4 pancreas, 1 renal, 1 unknown origin and 1 gallbladder), received 38 cycles, median 2 (1-12).
  • 1 CR (pancreas) and 1 PR (gallbladder) were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Kin T, Murdoch TB, Shapiro AMJ, Lakey JRT: Estimation of Pancreas Weight from Donor Variables. Cell Transplant; 2006 Feb;15(2):181-185
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of Pancreas Weight from Donor Variables.
  • Pancreas weight has not been considered as a donor selection criterion, because a value cannot be obtained prior to organ procurement.
  • However, a larger pancreas will likely contain a higher number of islets.
  • Therefore, the prediction of pancreas weight would be helpful in donor selection, benefiting cost and efficiency of the islet isolation laboratory.
  • The purpose of this study was to investigate normal pancreas weight in cadaveric donors and identify pancreas weight predictors from demographic data of cadaveric organ donors.
  • We retrospectively analyzed data on pancreas weight from 354 cadaveric donors with respect to gender, age, body weight, body height, body mass index (BMI), and body surface area (BSA).
  • In men, pancreas weight correlated more closely with body weight than with age, height, or BMI.
  • BSA was as strong a correlate of pancreas weight as body weight.
  • In women, pancreas weight had a similar pattern of relationships, with generally lower correlation coefficients.
  • On the basis of the observation of gender-specific pancreas weight difference in elderly donors, stepwise multiple linear regression analyses were conducted separately for younger (≥40 years) and elderly (≤41 years) donors.
  • In younger donors, body weight and age were the major predictors of pancreas weight [pancreas weight (g) = 4.355 + 0.742 × body weight (kg) + 0.837 × age (years) (R2 = 0.564, p < 0.001)].
  • In contrast, pancreas weight of elderly donors was best predicted by BSA and gender [pancreas weight (g) =-17.624 + 60.036 × BSA (m2) - 7.152 × gender (R2 = 0.372, p< 0.001; "gender": 1 = female, 0 = male)].
  • Pancreas weight was found to be positively associated with pre- and postpurification islet yields.
  • These formulae should contribute to the estimation of pancreas weight, and thus improve donor selection for islet isolation and transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28886278.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Body surface area / Cadaveric donor / Islet transplantation / Pancreas weight
  •  go-up   go-down


67. Shin S, Li N, Kobayashi N, Yoon JW, Jun HS: Remission of Diabetes by β-Cell Regeneration in Diabetic Mice Treated With a Recombinant Adenovirus Expressing Betacellulin. Mol Ther; 2008 May;16(5):854-861

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Type 1 diabetes results from destruction of the majority of the pancreatic β cells by β cell-specific autoimmune responses; therefore, expansion of the β-cell mass in vivo Is a possible approach to its treatment.
  • We investigated whether transient, constitutive expression, and secretion of BTC would regenerate sufficient numbers of pancreatic β cells to restore normoglycemia in diabetic animals.
  • Pancreatic insulin content, β-cell mass, and serum insulin levels in rAd-BTC-treated mice were significantly higher than in the controls.
  • We conclude that transient expression of BTC by rAd-BTC administration results in prolonged remission of diabetes in mice, by the regeneration of sufficient numbers of β cells in the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178488.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Trucco M: Is Facilitating Pancreatic Beta Cell Regeneration a Valid Option for Clinical Therapy? Cell Transplant; 2006 Jan;15(1_suppl):75-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is Facilitating Pancreatic Beta Cell Regeneration a Valid Option for Clinical Therapy?
  • There is accumulating evidence that the endocrine pancreas has regenerative properties, that hematopoietic chimerism can abrogate destruction of beta cells in autoimmune diabetes, and that, in this manner, physiologically sufficient endogenous insulin production can be restored in clinically diabetic NOD mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863766.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Autoimmunity / Beta cell precursors / Beta cell regeneration / Tolerization / Type 1 diabetes
  •  go-up   go-down


69. Noguchi H, Levy MF, Kobayashi N, Matsumoto S: Pancreas Preservation by the Two-Layer Method: Does it Have a Beneficial Effect Compared with Simple Preservation in University of Wisconsin Solution? Cell Transplant; 2009 May/Jun;18(5-6):497-504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreas Preservation by the Two-Layer Method: Does it Have a Beneficial Effect Compared with Simple Preservation in University of Wisconsin Solution?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880638.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenosine triphosphate / Islet isolation / Islet transplantation / Perfluorochemical / Two-layer method / University of Wisconsin solution
  •  go-up   go-down


70. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Infante JR, Jones SF, Bendell J, Spigel D, Barton J, Zubkus J, Byrne C, Griner P, Weekes C, Messersmith WA, Burris HA: Phase I dose escalation study of pomalidomide in combination with gemcitabine in patients (pts) with untreated metastatic carcinoma of the pancreas. J Clin Oncol; 2009 May 20;27(15_suppl):e15539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation study of pomalidomide in combination with gemcitabine in patients (pts) with untreated metastatic carcinoma of the pancreas.
  • Pomalidomide has immuno-stimulatory properties and effects on the tumor microenvironment including inhibition of inflammatory mediators, stromal cell support, endothelial cell function, and angiogenesis.
  • METHODS: Eligibility included pts with untreated metastatic pancreatic cancer, adequate organ function, ECOG 0-1, and willingness to take prophylactic anticoagulation with aspirin, low-dose coumadin, or low molecular weight heparin.
  • CONCLUSIONS: Dosing of pomalidomide daily for 21 days in combination with gemcitabine 1,000 mg/m2 given IV on day 1, 8, and 15 of a 28 day cycle was well tolerated and has promising clinical activity in patients with metastatic pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962320.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Ohorodnyk P, Eisenhauer EA, Booth CM: Clinical benefit in oncology trials: Is this a patient-centered or tumor-centered endpoint? J Clin Oncol; 2009 May 20;27(15_suppl):6564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical benefit in oncology trials: Is this a patient-centered or tumor-centered endpoint?
  • : 6564 Background: Clinical benefit (CB) was first successfully used as an endpoint in 1997 in the pivotal study of gemcitabine in advanced pancreas cancer.
  • CB was classified as tumor-centered if it related to objective tumor criteria for partial/complete response and/or stable disease.
  • RESULTS: 71 trials reporting CB as an endpoint were identified: 37 in breast, 8 in pancreas, and 26 in other cancers.
  • The definition of CB was patient-centered in 21 trials (30%) and tumor-centered in 50 trials (70%).
  • Only 20% (14/71) of trials (including all 8 pancreas studies) used the original Burris definition.
  • In the second half of the study period there was an increase in the number of trials using CB as an endpoint (17 to 54 trials) and in the proportion of trials with a tumor-centered definition (10/17, 59% to 41/54, 76%, p = 0.09).
  • Study variables associated with the use of a tumor-centered definition include: disease site (breast 35/37, 95%; all others 16/34, 47%, p < 0.001) and intervention (hormone or targeted agent 38/40, 95%; chemotherapy 13/31, 42%, p < 0.001).
  • CONCLUSIONS: Despite its initial definition, clinical benefit is often used to describe objective tumor findings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963802.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Wilson GD, Suen A, Robertson J, Galoforo S, Marples B: Sorafenib and radiation: A promising combination in colorectal and pancreas cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14622

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib and radiation: A promising combination in colorectal and pancreas cancer.
  • : e14622 Background: Sorafenib inhibits both RAF kinase, a critical component of the RAS/RAF/MEK/ERK signaling pathway that controls cell proliferation, and VEGFR-2/PDGFR-beta signaling cascade, blocking tumor angiogenesis; this dual activity has great potential for radiosensitization.
  • This study examines the effectiveness of radiation and sorafenib in a series of human colorectal and pancreatic cell lines and xenografts with differing ras mutational status.
  • Two pancreatic cancer cell lines were selected, Panc 03.27 is wild-type ras whilst Panc 02.03 has a mutation in codon 12.
  • In pancreatic cells, sorafenib was toxic at 10 μg/ml and reduced survival by 30% at 5 μg/ml without sensitization The endpoint in the xenograft studies was tumor growth to 2000mm<sup>3</sup> within a period of 120 days.
  • Phase I studies are under development in both pancreatic and colorectal cancer at our Instittution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964218.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Noguchi H, Ueda M, Hayashi S, Kobayashi N, Okitsu T, Iwanaga Y, Nagata H, Liu X, Kamiya H, Levy MF, Matsumoto S: Comparison of Trypsin Inhibitors in Preservation Solution for Islet Isolation. Cell Transplant; 2009 May/Jun;18(5-6):541-548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports show that the two-layer method (TLM), which employs oxygenated perfluorochemical (PFC) and University of Wisconsin (UW) solution, is superior to simple cold storage in UW for pancreas preservation in islet transplantation.
  • These data suggest that ET-Kyoto with ulinastatin was the better combination for pancreas preservation than ET-Kyoto with Pefabloc.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880641.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Islet isolation / Islet transplantation / MK solution / Preservation solution / Trypsin inhibitor
  •  go-up   go-down


75. Fan BG, Andrén-Sandberg Å: IV Hypertonic Glucose Stimulates the Exocrine Pancreas in Rat. JPEN J Parenter Enteral Nutr; 2006;30(1):40-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IV Hypertonic Glucose Stimulates the Exocrine Pancreas in Rat.
  • BACKGROUND: Pancreatic atrophy and dysfunction resulting from parenteral nutrition (PN) may be explained by several mechanisms; one of the important factors is the nutrient in the circulation, which affects the pancreatic growth and secretion.
  • The effect of nutrients on the pancreatic exocrine still has controversies.
  • The aim of the present study is to better understand the effect of IV glucose on the exocrine pancreas stimulated by cholecystokinin during the parenterally fed condition.
  • The body weight and pancreatic contents were measured after 10 days.
  • IV glucose caused a decrease in the pancreatic weight, the amount of the pancreatic protein and DNA, and the level of amylase but elevated the level of trypsin in all treated groups.
  • CONCLUSIONS: IV glucose results in atrophy of the exocrine pancreas, elevates the amylase in pancreas, but suppresses the stimulatory effect of cholecystokinin on the exocrine pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28059014.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Harrell FE, Rodell T, Apelian D: Case study of a flexible bayesian design in a phase II study in patients with resected pancreas cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15651

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case study of a flexible bayesian design in a phase II study in patients with resected pancreas cancer.
  • : e15651 Background: This presentation will describe a Bayesian flexible design for an ongoing randomized, placebo controlled phase II trial in newly diagnosed, resected pancreas cancer comparing gemcitabine plus therapeutic vaccine (GI-4000) vs. gemcitabine alone.
  • CONCLUSIONS: In the frequentist approach, computing the probability of getting a result as or more impressive than that observed if there is truly no treatment effect (the P-value) requires contemplating experiments that were never carried out and analyses that were never done.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962790.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Oishi K, Noguchi H, Yukawa H, Hayashi S: Differential Ability of Somatic Stem Cells. Cell Transplant; 2009 May/Jun;18(5-6):581-590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we investigated the transdifferentiation potential of somatic stem cells using adipose tissue-derived stem/progenitor cells (ASCs; mesodermal stem cells) and pancreatic stem cells (endodermal stem cells).
  • Unlike previous reports, we did not get ASCs to express any pancreas-specific genes, including insulin-1 or insulin-2.
  • Pancreatic stem cells were induced to differentiate into adipo/osteogenic by the following protocols.
  • Although these approaches have been widely used for adipo/osteogenic differentiation from MSCs, adipo/osteogenic differentiation from pancreatic stem cells was not observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880631.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adipose tissue-derived stem/progenitor cells (ASCs) / Differential ability / Pancreatic stem cells / Somatic stem cells
  •  go-up   go-down


78. Vaitheeswaran R, Sathiya Narayanan VK, Bhangle JR, Nirhali A, Kumar N, Basu S, Maiya V: An algorithm for fast beam angle selection in intensity modulated radiotherapy. Med Phys; 2010 Dec;37(12):6443-6452

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the efficiency of the algorithm was examined in three clinical cases (prostate, pancreas, and head and neck) in terms of DVH and dose distribution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524935.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Annealing / Cancer / Dose-volume analysis / Dosimetry / Intensity modulated radiation therapy / Kidneys / Numerical solutions / Optimization / Photons / Researchers / Treatment strategy / beam angle selection / beam angles / dosimetry / intensity modulated radiotherapy (IMRT) / intensity modulation / inverse planning / kidney / optimisation / phantoms / radiation therapy / radiotherapy
  •  go-up   go-down


79. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A: Robotic radiosurgery of liver metastases of solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with liver metastases not qualifying for surgery were treated with single session radiosurgery (24 Gy) using robotic image-guided real-time tumor tracking.
  • For inclusion into the radiosurgery treatment protocol, tumor volumes had to be smaller than 80cc.
  • Metastases (n=27) originated from: colon (12), rectum (2), pancreas (2), lung (1), bladder (2), malignant melanoma (1), stomach (1), cholangiocellular carcinoma (2), breast (1), ovary (1), appendix (1) and endometrium (1).
  • Median tumor volume was 21cc (range 2.2-79.3).
  • CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver metastases is a new and promising treatment approach for pts not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Hörsch D, Prasad V, Ambrosini V, Hommann M, Fanti S, Baum RP: Detection of unknown primary neuroendocrine tumors (CUP-NET) using &lt;sup&gt;68&lt;/sup&gt;Ga DOTA-NOC receptor PET/CT. J Clin Oncol; 2009 May 20;27(15_suppl):4599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The maximum standardised uptake values (SUVmax) were calculated and compared with SUVmax in known pancreatic NET (pNET) and ileum / jejunum / duodenum (SI-NET).
  • RESULTS: In 35/59 (59%) of patients, <sup>68</sup>Ga-DOTA-NOC PET/CT localised the site of the primary: ileum/jejunum (14), pancreas (16), rectum (2), lungs (2) and paraganglioma (1).
  • The SUVmax of the unknown pNET and SI-NET were significantly lower (p< 0.05) as compared to the ones with known primary tumour sites.
  • In 4/59 patients the primary tumour was subsequently resected (2 pancretic, one ileal and one rectal tumour).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963110.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Salerrno May KS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M: Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e15532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary disease sites were pancreas (61.5%), periampullary (16.1%), stomach (10.8%), gastroesophageal junction (10%), and retroperitoneum (1.5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Trivanovic D, Dobrila-Dintinjana R, Mavric Z, Stimac D, Petkovic M: QTc interval in advanced cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary site of disease was lung (28%), pancreas (19%), colon (15%), rectum (13%), breast (12%), and other (13%).
  • CONCLUSIONS: The results of our study indicate that a prolonged QTc interval (> 440 ms) is an adverse prognostic sign in patients with advanced cancer and without cardiac disease which correlates with increased mortality rates within one year after the diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961619.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Levine MN, Deitchman D, Julian J, Liebman H, Escalante C, O'Brien MC, Ramirez L, Weise-Kelly L, Solymoss S: A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancers were breast, colon, pancreas, and myeloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960918.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Han HS, Min SK, Lee HK, Kim SW, Park YH: Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for benign pancreas neoplasm. Surg Endosc; 2005 Oct;19(10):1367-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for benign pancreas neoplasm.
  • BACKGROUND: Laparoscopic distal pancreatectomy to conserve the spleen is a beneficial operation for patients with benign and borderline malignancy in the pancreas.
  • METHODS: From May 2000 to July 2003, five laparoscopic distal pancreatectomies with preservation of the spleen and splenic vessels were performed for benign pancreas neoplasm at Ewha Womans University Mokdong Hospital in Seoul, Korea.
  • RESULTS: The postoperative pathologic diagnoses were two serous cystadenomas, two mucinous cystadenomas, and one solid and papillary epithelial tumor.
  • Four trocars (10-15 mm) and a laparoscopic linear stapler were used for transection of the pancreas.
  • CONCLUSION: Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels is a relatively safe and feasible option for the management of benign tumor or borderline malignancy in the distal pancreas.
  • [MeSH-major] Laparoscopy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 1999 Aug;9(4):290-3 [10871180.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):402-6 [14735345.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):154-64 [10398903.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1358-61 [11984672.001]
  • [Cites] Surg Endosc. 1999 Jan;13(1):26-9 [9869683.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):996-1003 [12163971.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):217-8 [11961650.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):359-61 [9408401.001]
  • [Cites] Surg Endosc. 2001 Jul;15(7):759 [11591991.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):149-58 [12170019.001]
  • [Cites] Am J Surg. 1996 Oct;172(4):320-3 [8873521.001]
  • [Cites] Surg Endosc. 1994 Jan;8(1):57-60; discussion 60-1 [8153866.001]
  • (PMID = 16193376.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


85. Kawamoto S, Horton KM, Lawler LP, Hruban RH, Fishman EK: Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT? Radiographics; 2005 Nov-Dec;25(6):1451-68; discussion 1468-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT?
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct clinicopathologic entity that is being recognized with increasing frequency.
  • Features predictive of invasive carcinoma in IPMN at CT and other imaging studies include involvement of the main pancreatic duct, marked dilatation of the main pancreatic duct, diffuse or multifocal involvement, the presence of a large mural nodule or solid mass, large size of the mass, and obstruction of the common bile duct.
  • [MeSH-major] Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Papillary / radiography. Neoplasms, Multiple Primary / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005.
  • (PMID = 16284127.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


86. Igaz P, Igaz I, Rácz K, Tulassay Z: [Hereditary tumours of the endocrine pancreas]. Orv Hetil; 2006 Feb 5;147(5):195-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hereditary tumours of the endocrine pancreas].
  • [Transliterated title] Az endokrin pancreas öröklódó daganatai.
  • The pathogenesis, diagnosis and therapy of tumours originating from the endocrine pancreas represent one of the most exciting challenges of contemporary medicine.
  • Some of these tumours appear as part of four hereditary syndromes (multiple endocrine neoplasia type 1 (MEN1), von Hippel-Lindau disease (VHL), neurofibromatosis type 1 and tuberous sclerosis) that are all inherited as autosomal dominant traits and result from mutations of tumour suppressor genes.
  • Tumours of the endocrine pancreas develop in 30-80% of patients carrying mutations of the MEN1 gene.
  • Tumours of the endocrine pancreas are infrequent in patients suffering from VHL, neurofibromatosis and tuberous sclerosis.
  • In this review article, the authors present a synopsis of tumours of the endocrine pancreas related to these hereditary syndromes underlining the clinical characteristics, diagnostical and therapeutical possibilities.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Gastrinoma / diagnosis. Gastrinoma / genetics. Glucagonoma / genetics. Humans. Insulinoma / diagnosis. Insulinoma / genetics. Mass Screening. Multiple Endocrine Neoplasia Type 1 / complications. Neurofibromatosis 1 / complications. Somatostatinoma / genetics. Tuberous Sclerosis / complications. Vipoma / genetics. von Hippel-Lindau Disease / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509219.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 50
  •  go-up   go-down


87. Tihanyi Z, Luka F, Botos B, Horváth L, Szontagh-Kisházi P, Altorjay A: [Antral ectopic pancreas causing gastric outlet obstruction]. Magy Seb; 2005 Oct;58(5):331-3
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antral ectopic pancreas causing gastric outlet obstruction].
  • [Transliterated title] Gyomorürülési zavart okozó antrális ectopiás pancreas.
  • Ectopic pancreas is an uncommon clinical finding.
  • It is rare for heterotopic pancreas tissue to cause symptoms, however every disease of the pancreas may develop in it.
  • The most common sites for ectopic pancreas are the submucosal layer of the stomach and the small intestine.
  • Symptomatic ectopic pancreas usually causes diagnostic difficulties.
  • We performed subtotal gastrectomy because of a submucosal, antral tumour, that caused gastric outlet obstruction.
  • The histological examination verified ectopic pancreas tissue.
  • [MeSH-major] Choristoma. Gastric Outlet Obstruction / etiology. Pancreas. Pyloric Antrum. Stomach Diseases
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496778.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


88. Dima S, Braşoveanu V, Hrehoreţ D, Matei E, Turcu R, Zamfir R, Popescu I: [Human pancreas procurement for pancreas and islet transplantation]. Chirurgia (Bucur); 2007 Jan-Feb;102(1):19-26
MedlinePlus Health Information. consumer health - Pancreas Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human pancreas procurement for pancreas and islet transplantation].
  • [Transliterated title] Prelevarea pancreasului uman pentru transplantul de pancreas şi de insule pancreatice.
  • Integral pancreatic transplantation and islet cell transplantation represent two possibilities of replacing the beta islet cells.
  • The aim of this paper is to analyze the main aspects of selection criteria of the pancreas donor and surgical methods of preservation for integral pancreas or islet cell transplantation.
  • There are described the pancreas procurements realized by the Center of General Surgery and Liver Transplantation team from Fundeni Clinical Institute between December 2005-December 2006 and correlation between the donor's and pancreas features and the quality of islet cell isolation.
  • The selection of pancreas donor and the accomplishment of pancreas procurement represent important factors in the post-transplantation course of the graft.
  • The data from pancreas/islet cell transplantation centers suggest that the factors that influence positively the course of graft are: the donor's age, body mass index, cold ischemia time.
  • [MeSH-major] Diabetes Mellitus, Type 1 / surgery. Islets of Langerhans Transplantation / methods. Pancreas / blood supply. Pancreas Transplantation / methods. Pancreatectomy / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Islet Cell Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410725.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 61
  •  go-up   go-down


89. Vasile D, Grigoriu M, Turcu F, Ilco A, Tenovici G, Vasile R: [Pancreas divisum--a rare cause of chronic pancreatitis]. Chirurgia (Bucur); 2007 Jan-Feb;102(1):83-7
Genetic Alliance. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreas divisum--a rare cause of chronic pancreatitis].
  • [Transliterated title] Pancreas divisum--cauza rara de pancreatita cronica.
  • Pancreas divisum (P.D.) is a congenital anatomic variant, characterized by the nonunion of dorsal and ventral pancreatic ducts.
  • His pain resolved following surgical drainage of the pancreatic duct.
  • Evaluation of the clinical course of this patient and critical review of other such cases in the literature support the role of compromised ductal drainage of the pancreas in the pathogenesis of chronic pancreatitis in P.D.
  • [MeSH-major] Pancreas / abnormalities. Pancreatitis, Chronic / diagnosis. Pancreatitis, Chronic / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410736.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


90. Wientjes CA, Koedam NA, van Keulen EM, Naber AH: [Cystic abnormalities of the pancreas: inflammatory pseudocyst or neoplasm]. Ned Tijdschr Geneeskd; 2008 Aug 2;152(31):1737-42
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystic abnormalities of the pancreas: inflammatory pseudocyst or neoplasm].
  • [Transliterated title] Cysteuze afwijkingen van het pancreas: inflammatoire pseudocyste of neoplasma.
  • Based on the medical history, physical examination and findings from radiological examination, initially the diagnosis was 'chronic pancreatitis with formation ofa pseudocyst caused by alcohol abuse'.
  • After one week the patient developed cholestatic liver function disorders with elevated serum pancreatic enzymes.
  • A CT scan of the abdomen showed a dilated gallbladder and progression of the cystic lesion in the pancreatic head with compression of the distal common bile duct.
  • An endoscopic retrograde cholangiopancreatography was performed and the findings fitted a diagnosis of an intraductal papillary mucinous neoplasm.
  • Differentiation between an inflammatory or neoplastic origin of cystic lesions in the pancreas can be difficult.
  • There is a risk ofmisdiagnosing a cystic neoplasm for a pseudocyst.
  • This may lead to delays in making the correct diagnosis.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde / methods. Cystadenoma, Mucinous / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatic Pseudocyst / diagnosis
  • [MeSH-minor] Acute Disease. Aged. Diagnosis, Differential. Female. Humans. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18727606.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Aloui-Kasbi N, Mbarek S, Bellagha I, Hammou A: [Primary T-cell lymphoma of the pancreas in children]. Tunis Med; 2005 Feb;83(2):114-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary T-cell lymphoma of the pancreas in children].
  • [Transliterated title] Lymphome T primaire du pancreas chez l'enfant.
  • Involvement of the gastrointestinal tract is frequently reported among the extranodal sites of non-Hodgkin's lymphoma, but primary lymphoma of the pancreas is very rare.
  • We report the case of a 11-year-old boy explored for epigastric pain with fever leading to the diagnosis of high-grade primary non Hodgkin's T-cell lymphoma, originating from pancreas.
  • This pancreatic lesion is documented by sonography, CT and MRI.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969235.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


92. van Wensen RJ, Bosscha K, Jager GJ, van der Linden JC, Fijnheer R: [An invasive process in the pancreas: sometimes lymphoma]. Ned Tijdschr Geneeskd; 2009;153:B164
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An invasive process in the pancreas: sometimes lymphoma].
  • [Transliterated title] Een ruimte-innemend proces in het pancreas: soms een lymfoom.
  • An invasive process in the pancreas was found in a 60-year-old woman and a 50-year-old man with abdominal symptoms.
  • Primary pancreatic lymphoma or localization of lymphoma in the pancreas are rare and chemotherapy may be curative.
  • Therefore, obtaining tissue for histopathological confirmation of the diagnosis is very important.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818177.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


93. De Raffele E, Mirarchi M, Vaccari S, Santini D, Calculli L, Pendino GM, Cola B: [Echo-guided spleen-preserving resection of the pancreas tail for pancreatic intraductal papillary mucinous neoplasms]. Chir Ital; 2009 Sep-Dec;61(5-6):667-77
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Echo-guided spleen-preserving resection of the pancreas tail for pancreatic intraductal papillary mucinous neoplasms].
  • [Transliterated title] Resezione della coda del pancreas "spleen preserving" ecoguidata per neoplasia intraduttale mucinosa (IPMN) del pancreas.
  • Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are a distinct entity with malignant potential, which may recur after surgical excision.
  • We report our technique of intraoperative US-guided resection of non-invasive IPMNs located in the tail of the pancreas with spleen and splenic vessel preservation.
  • Following adequate exposure of the distal pancreas, a thorough ultrasonographic examination of the parenchyma is accomplished to define the features of the neoplasia, its relationship with the main pancreatic duct and splenic vessels and to mark the transection line with electrocautery.
  • Dissection begins at the inferior edge of the pancreatic tail and proceeds in a lateral to medial direction up to the transection line.
  • The main pancreatic duct is identified and sutured, the parenchyma is then closed and the suture line is reinforced with a fibrinogen/thrombin-coated collagen patch.
  • Patient 1 was a 63-year-old male who underwent intraoperative US-guided resection of the pancreatic tail for an IPMN of the pancreatic tail measuring 28 mm with moderate dysplasia at histology, and was discharged 9 days after surgery.
  • Patient 2 was a 60-year-old male who underwent intraoperative US-guided resection of the pancreatic tail for an IPMN of the pancreatic tail measuring 30 mm with carcinoma in situ at histology, and was discharged 9 days after surgery.
  • Limited distal pancreatic resection with spleen and splenic vessel preservation is an adequate surgical technique for non-invasive IPMN of the tail of the pancreas.
  • Intraoperative ultrasonography is crucial in planning "radical but conservative" pancreatic resection.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / ultrasonography. Spleen

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380276.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


94. Danzi M, Grimaldi L, Reggio S, Giordano M, Caterino M, Danzi R: [Solid pseudo papillary tumor of the pancreas: case report and literature review]. G Chir; 2008 Jun-Jul;29(6-7):271-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solid pseudo papillary tumor of the pancreas: case report and literature review].
  • [Transliterated title] Tumore solido pseudopapillare del pancreas. Caso clinico e revisione della letteratura.
  • Solid pseudopapillary neoplasm (SPT) of the pancreas is a rare exocrine tumor, for the first time described from Frantz et al. in 1959.
  • Despite the increasing recognition of the tumor in this last year, its pathogenesis remain unclear.
  • The Authors report the case of a 24 years-old woman with an abdominal mass localized in retro-peritoneum, removed with body-tail of the pancreas and spleen, diagnosed as pancreatic SPT after histological examination.
  • [MeSH-major] Cystadenoma, Papillary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544263.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 19
  •  go-up   go-down


95. Minetti E, Colussi G: [Renal outcome after pancreas transplant in patients with unstable diabetes mellitus]. G Ital Nefrol; 2010 Nov-Dec;27 Suppl 52:S78-81
MedlinePlus Health Information. consumer health - Pancreas Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal outcome after pancreas transplant in patients with unstable diabetes mellitus].
  • [Transliterated title] Outcome renale dopo trapianto di pancreas nel diabete mellito instabile.
  • Combined kidney-pancreas transplant is currently the best treatment option for patients with type 1 diabetes associated with chronic renal failure.
  • The favorable results of simultaneous pancreas-kidney transplants (SPK), introduced in the early 1990s, led to the introduction of the pancreas after kidney transplant (PAK) and the pancreas transplant alone (PTA), a good option for patients with uncontrolled diabetes.
  • In conclusion, PAK transplant is a good preemptive choice for patients for whom a living kidney donor is available, so that long-term uremia while the patient is waiting for a cadaver pancreas graft can be avoided.
  • Despite a high surgical complication rate in all types of pancreas transplant (SPK, PAK, PTA), patient survival is good and graft survival is improving year by year.
  • [MeSH-major] Diabetes Mellitus / surgery. Kidney Transplantation. Pancreas Transplantation

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21132667.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Hajdú N, Belágyi T, Gyurus P, Oláh A: [Solid pseudopapillary neoplasm of the pancreas]. Magy Seb; 2008 Apr;61(2):65-70
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solid pseudopapillary neoplasm of the pancreas].
  • [Transliterated title] A pancreas solid pseudopapillaris tumora.
  • Solid pseudopapillary neoplasms (SPN) of the pancreas are rare tumours with low malignant potential, usually affecting young women.
  • Due to its relatively low incidence, there are no international guidelines published on diagnosis or treatment.
  • In all cases SPN was diagnosed preoperatively on the basis of CT-findings and the diagnosis was confirmed by postoperative histology.
  • After an organ-preserving radical resection of the tumour, all patients have remained disease free with an acceptable quality of life so far.
  • Our data suggest that CT-scan is adequate to establish the preoperative diagnosis of SPN.
  • [MeSH-major] Carcinoma, Papillary. Pancreatectomy. Pancreatic Neoplasms. Pancreatic Pseudocyst

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426709.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


97. Solecki R, Kedra B, Czupryna A, Nowak K: [Solid and papillary epithelial neoplasm of the pancreas--a rare malignant tumor of pancreas]. Przegl Lek; 2005;62(12):1570-2
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solid and papillary epithelial neoplasm of the pancreas--a rare malignant tumor of pancreas].
  • [Transliterated title] Solid and papillary epithelial neoplasm of the pancreas--rzadki guz nowotworowy trzustki.
  • The paper presents two cases of solid and papillary epithelial neoplasm of the pancreas (SPENP)--a rare pancreatic neoplasm in a 45-year-old woman admitted to the hospital with the diagnosis of pancreatic tail tumor and 22-year-old woman with the diagnosis of pancreatic head tumor.
  • First patient was subjected to peripheral pancreatic resection; the second patient was subjected to Whipple pancreatoduodenectomy.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786800.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


98. Yimcharoen P, Fogel EL, McHenry L, Watkins J, Sherman S, Lehman GA: [State-art: diagnosis and management in pancreas divisum]. Rev Gastroenterol Mex; 2005 Jul;70 Suppl 1:133-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [State-art: diagnosis and management in pancreas divisum].
  • [Transliterated title] Ultimos adelantos: diagnóstico y tratamiento del pancreas divisum.
  • Pancreas divisum (PD), the most common congenital variant of pancreatic duct anatomy, occurs when the ductal systems of the ventral and dorsal pancreatic ducts fail to fuse during the second month of gestation.
  • With non-union of the ducts, the major portion of the pancreatic exocrine secretion enters the duodenum by way of the dorsal duct and minor papilla.
  • It has been generally accepted that a relative obstruction to pancreatic exocrine secretory flow through the minor duct and minor papilla could result in pancreatitis in small numbers of patients with PD.
  • Endoscopic retrograde cholangiopancreatography (ERCP) is the most common procedure for diagnosis PD in patients who have pancreatobiliary symptoms.
  • MRCP is being increasingly used to establish the diagnosis and secretin stimulation can improve ductal images greatly.
  • Only a limited number of series are available, using endoscopic pancreatic stent placement, minor papilla endoscopic papillotomy, or both to decompress the dorsal duct in an effort to restore pancreatic exocrine secretory flow.
  • Overall we recommend that pancreatic stenting and pancreatic sphincterotomy should be done only in large centers with experience in therapeutic ERCP.
  • [MeSH-major] Pancreas / abnormalities. Pancreatic Ducts / abnormalities. Pancreatitis / etiology
  • [MeSH-minor] Acute Disease. Constriction, Pathologic. Diagnosis, Differential. Endoscopy. Humans. Prospective Studies. Prosthesis Implantation. Randomized Controlled Trials as Topic. Recurrence. Sphincterotomy, Endoscopic

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469416.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 75
  •  go-up   go-down


99. Abad Licham M, Sanchez Lihon J, Celis Zapata J: [Pseudopapillary solid tumor of pancreas in the INEN]. Rev Gastroenterol Peru; 2008 Oct-Dec;28(4):356-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudopapillary solid tumor of pancreas in the INEN].
  • [Transliterated title] Tumor sólido pseudopapilar de pancreas en el INEN.
  • OBJECTIVE: To determine the frequency of pancreas solid-pseudopapillary tumor (SPT) and to describe its clinical, pathological and immunohistochemical features in the National Institute of Neoplasic Diseases (INEN).
  • RESULTS: The SPT accounts for 3.7% of pancreatic tumors in the INEN.
  • The average tumor size was 10.0 cm. and the most frequent location was the head of the pancreas.
  • Histologically is a monoforme pattern neoplasia, that displays pseudopapillae, rosettes, cholesterol crystals, sclerosis and calcification.
  • CONCLUSIONS: SPT is uncommon tumor with clinical, pathological and inmunohistochemical defined features.
  • It is less aggressive than other pancreatic tumors, nevertheless its uncertain behavior demands follow up.
  • [MeSH-major] Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156179.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


100. Vinco A, Cimaschi D, Pulcini G, Chiametti G, De Cesare V, Frassi E, Cervi GC: [Mucinous cystic tumour of the pancreas. A case report]. Chir Ital; 2006 May-Jun;58(3):367-72
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous cystic tumour of the pancreas. A case report].
  • [Transliterated title] A proposito di un caso di tumore cistico mucinoso del pancreas.
  • Although cystic neoplasms and lesions of the pancreas are rare (5% of exocrine tumours), they have attracted a great deal of attention because of their potential curability.
  • In contrast to serous cystic neoplasms, which are generally benign, the mucinous variant is known to have considerable malignant potential.
  • Most authorities agree that no imaging technique (US, CT, MRI) is sufficiently accurate to differentiate between the multiple benign, premalignant and malignant lesions that can be visualised.
  • We report a case of a young woman with a mucinous cystic tumour of the pancreas which was successfully treated surgically and compare our data with those emerging from a review of the literature.
  • CT scan suggested a mucinous cystic neoplasm of the pancreas.
  • We treated the patient surgically, performing resection of the neoplasm with left pancreatectomy.
  • The histological examination revealed a benign pancreatic cystadenoma.
  • Mucinous cystic neoplasms of the pancreas have a substantial malignant potential and should be treated surgically with adequate resection margins.
  • [MeSH-major] Cystadenoma / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845875.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 29
  •  go-up   go-down






Advertisement